MCID: NRM001
MIFTS: 64

Neuromyelitis Optica

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuromyelitis Optica

MalaCards integrated aliases for Neuromyelitis Optica:

Name: Neuromyelitis Optica 39 12 54 26 55 60 38 56 45 15 17 74
Devic Syndrome 77 54 26
Devic Disease 54 26 60
Devic's Syndrome 12 55
Devic's Disease 12 26
Opticospinal Multiple Sclerosis 74
Devic's Neuromyelitis Optica 54
Devic Neuromyelitis Optica 26
Nmo Spectrum Disorder 54
Optic-Spinal Ms 26
Opticospinal Ms 26
Nmo 54

Characteristics:

Orphanet epidemiological data:

60
neuromyelitis optica
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:8869
KEGG 38 H01491
ICD9CM 36 341.0
MeSH 45 D009471
NCIt 51 C84934
SNOMED-CT 69 25044007
ICD10 34 G36.0
MESH via Orphanet 46 D009471
ICD10 via Orphanet 35 G36.0
UMLS via Orphanet 75 C0027873
Orphanet 60 ORPHA71211

Summaries for Neuromyelitis Optica

NINDS : 55 Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord. It is sometimes also referred to as NMO spectrum disorder. In NMO, the body's immune system mistakenly attacks healthy cells and proteins in the body, most often those in the spinal cord and eyes. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss. Individuals also develop transverse myelitis, which causes weakness or paralysis of arms and legs,and numbness, along with loss of bladder and bowel control. Magnetic resonance imaging of the spine often shows an abnormality that extends over long segments of the spinal cord. Individuals may also develop episodes of severe nausea and vomiting, with hiccups from involvement of a part of the brain that controls vomiting. The disease is caused by abnormal autoantibodies that bind to a protein called aquaporin-4. Binding of the aquaporin-4 antibody activates other components of the immune system, causing inflammation and damage to these cells. This also results in the brain and spinal cord the loss of myelin, the fatty substance that acts as insulation around nerve fibers and helps nerve signals move from cell to cell.  NMO is different from multiple sclerosis (MS). Attacks are usually more severe in NMO than in MS, and NMO is treated differently than MS. Most individuals with NMO experience clusters of attacks days to months or years apart, followed by partial recovery during periods of remission. Women are more often affected by NMO than men. African Americans are at greater risk of the disease than are Caucasians. The onset of NMO varies from childhood to adulthood, with two peaks, one in childhood and the other in adults in their 40s.

MalaCards based summary : Neuromyelitis Optica, also known as devic syndrome, is related to neuritis and optic neuritis. An important gene associated with Neuromyelitis Optica is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Mitoxantrone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, brain and spinal cord, and related phenotypes are visual loss and peripheral demyelination

Disease Ontology : 12 A central nervous system disease characterized by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).

Genetics Home Reference : 26 Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.

NIH Rare Diseases : 54 Neuromyelitis optica is an autoimmune disease that affects the spinal cord and optic nerves (nerves that carry visual messages to and from the brain). In neuromyelitis optica, the body's immune system mistakenly attacks healthy cells and a substance called myelin in the spinal cord and eyes. Symptoms may begin in childhood or adulthood. Spinal cord involvement results in transverse myelitis, which may cause pain, paralysis and abnormal sensations in the spine and limbs. Bladder and bowel problems may also develop. Symptoms from optic nerve involvement include eye pain and vision loss from optic neuritis. Other symptoms of neuromyelitis optica may include episodes of nausea, vomiting, and hiccups. Some people have episodes of symptoms months or years apart (the relapsing form), while others have a single episode lasting several months (the monophasic form). In either form, people with neuromyelitis optica often develop permanent muscle weakness and vision loss. The cause of the immune system dysfunction leading to neuromyelitis optica is not known. It usually occurs in only one person in a family. There is no cure, but there are therapies to reduce symptoms during episodes and prevent relapses.

Wikipedia : 77 Neuromyelitis optica (NMO), also known as Devic''s disease or Devic''s syndrome, is a heterogeneous... more...

Related Diseases for Neuromyelitis Optica

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
# Related Disease Score Top Affiliating Genes
1 neuritis 31.7 AQP4 MBP MOG
2 optic neuritis 31.5 AQP4 HLA-DRB1 MBP MOG
3 encephalitis 31.2 AQP4 GFAP MOG
4 transverse myelitis 31.1 AQP4 IL17A IL6 MBP
5 optic nerve disease 31.0 AQP4 MBP MOG
6 allergic encephalomyelitis 30.8 MBP MOG
7 acute transverse myelitis 30.8 AQP4 IL6
8 multiple sclerosis 30.7 AQP4 GFAP HLA-DRB1 IL17A IL6 MBP
9 demyelinating disease 30.6 AQP4 IL17A MBP MOG
10 myelitis 30.6 AQP4 HLA-DPB1 IL17A IL6 MBP MOG
11 hypersomnia 30.6 HCRT HLA-DRB1
12 narcolepsy 30.5 HCRT HLA-DRB1 MOG
13 peripheral nervous system disease 30.4 AQP4 IL6 MBP MOG
14 panencephalitis, subacute sclerosing 30.4 MBP MOG
15 wernicke encephalopathy 30.4 GFAP SLC1A2
16 acute disseminated encephalomyelitis 30.3 AQP4 HCRT HLA-DRB1 MBP MOG
17 relapsing-remitting multiple sclerosis 30.3 AQP4 IL17A MBP MOG
18 radiculopathy 30.3 IL17A IL6
19 internuclear ophthalmoplegia 30.2 AQP4 HCRT MBP MOG
20 systemic lupus erythematosus 30.2 HLA-DPB1 HLA-DRB1 IL17A IL6 TNFSF13B
21 connective tissue disease 30.2 HLA-DPB1 HLA-DRB1 IL6 TNFSF13B
22 autoimmune disease 30.1 HLA-DRB1 IL17A IL6 MBP MOG TNFSF13B
23 takayasu arteritis 30.0 HLA-DPB1 HLA-DRB1 IL6
24 brain injury 29.8 GFAP IL6 MBP S100B
25 primary progressive multiple sclerosis 29.8 HLA-DRB1 MBP MOG S100B
26 neuromyelitis optica spectrum disorder 12.8
27 marburg acute multiple sclerosis 11.5
28 sjogren syndrome 10.7
29 lupus erythematosus 10.6
30 myasthenia gravis 10.5
31 myasthenia gravis congenital 10.5
32 neuropathy 10.5
33 encephalopathy 10.4
34 autoimmune disease 1 10.4
35 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
36 adenocarcinoma 10.4
37 depression 10.4
38 alexia 10.4 AQP4 MBP
39 chiari malformation 10.4 GFAP MBP
40 obstructive hydrocephalus 10.4 AQP4 GFAP
41 anca-associated vasculitis 10.3 HLA-DRB1 IL6
42 celiac disease 1 10.3
43 hematopoietic stem cell transplantation 10.3
44 hepatitis 10.3
45 pediatric multiple sclerosis 10.3 HLA-DRB1 MOG
46 rheumatoid arthritis, systemic juvenile 10.3 HLA-DRB1 IL6
47 ascaris lumbricoides infection 10.3 IL6 TNFSF13B
48 pulmonary tuberculosis 10.3
49 dystonia 10.3
50 leber hereditary optic neuropathy 10.3

Graphical network of the top 20 diseases related to Neuromyelitis Optica:



Diseases related to Neuromyelitis Optica

Symptoms & Phenotypes for Neuromyelitis Optica

Human phenotypes related to Neuromyelitis Optica:

60 33 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 visual loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0000572
2 peripheral demyelination 60 33 hallmark (90%) Very frequent (99-80%) HP:0011096
3 sensory impairment 60 33 hallmark (90%) Very frequent (99-80%) HP:0003474
4 optic neuritis 60 33 hallmark (90%) Very frequent (99-80%) HP:0100653
5 neuronal loss in central nervous system 60 33 hallmark (90%) Very frequent (99-80%) HP:0002529
6 ocular pain 60 33 hallmark (90%) Very frequent (99-80%) HP:0200026
7 autoimmune antibody positivity 60 33 hallmark (90%) Very frequent (99-80%) HP:0030057
8 paraplegia 60 33 hallmark (90%) Very frequent (99-80%) HP:0010550
9 functional abnormality of the bladder 60 33 hallmark (90%) Very frequent (99-80%) HP:0000009
10 myelitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0012486
11 abnormality of brain morphology 60 33 frequent (33%) Frequent (79-30%) HP:0012443
12 recurrent singultus 60 33 occasional (7.5%) Occasional (29-5%) HP:0100247
13 respiratory failure 60 33 occasional (7.5%) Occasional (29-5%) HP:0002878
14 nausea 60 33 occasional (7.5%) Occasional (29-5%) HP:0002018
15 csf pleocytosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0012229

MGI Mouse Phenotypes related to Neuromyelitis Optica:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 AQP1 AQP4 GFAP HCRT IL6 MBP
2 growth/size/body region MP:0005378 9.81 AQP1 AQP4 GFAP HCRT IL17A IL6
3 hematopoietic system MP:0005397 9.56 AQP1 AQP4 CD59 IL17A IL6 MBP
4 homeostasis/metabolism MP:0005376 9.32 AQP1 AQP4 CD59 GFAP HCRT IL17A

Drugs & Therapeutics for Neuromyelitis Optica

Drugs for Neuromyelitis Optica (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Topoisomerase Inhibitors Phase 4
6 Analgesics Phase 4
7 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
9 Antitubercular Agents Phase 4
10 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Antibiotics, Antitubercular Phase 4
13 Anti-Bacterial Agents Phase 4
14 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1
16 Anti-Infective Agents Phase 4
17
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1 302-25-0
18
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
19
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1 2921-57-5
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
21
Azathioprine Approved Phase 2, Phase 3,Phase 3 446-86-6 2265
22
rituximab Approved Phase 2, Phase 3,Phase 3,Phase 1 174722-31-7 10201696
23
Mesna Approved, Investigational Phase 2, Phase 3,Phase 1 3375-50-6 598
24
Ifosfamide Approved Phase 2, Phase 3,Phase 1 3778-73-2 3690
25
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
26
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 1 135968-09-1
27
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
28
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Phase 1 2920-86-7
29 Neuroprotective Agents Phase 3,Phase 2,Phase 1
30 Protective Agents Phase 3,Phase 2,Phase 1
31 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
32 Antiemetics Phase 3,Phase 2,Phase 1
33 Methylprednisolone Acetate Phase 3,Phase 2,Phase 1
34 Prednisolone acetate Phase 3,Phase 2,Phase 1
35 Autonomic Agents Phase 3,Phase 2,Phase 1
36 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
37 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
38 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimetabolites Phase 2, Phase 3,Phase 3
40 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
41 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
42 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
43 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
44 Rho(D) Immune Globulin Phase 2, Phase 3,Phase 3
45 Immunoglobulins, Intravenous Phase 2, Phase 3,Phase 3
46 gamma-Globulins Phase 2, Phase 3,Phase 3
47 Immunoglobulin G Phase 3,Phase 2
48
Isophosphamide mustard Phase 2, Phase 3,Phase 1 0
49 polysaccharide-K Phase 2, Phase 3,Phase 1
50 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
2 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
3 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Completed NCT01892345 Phase 3 Eculizumab
7 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
8 Autologous Transplant To End NMO Spectrum Disorder Recruiting NCT03829566 Phase 2, Phase 3 Rituximab;Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
9 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
10 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT02200770 Phase 2, Phase 3
11 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Active, not recruiting NCT02003144 Phase 3
12 Efficacy and Safety Study as Monotherapy of Satralizumab (SA237) to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
13 Efficacy and Safety Study as Add-on Therapy of Satralizumab (SA237) to Treat NMO and NMOSD Active, not recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
14 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
15 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
16 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
17 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
18 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
19 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Completed NCT02893111 Phase 2 Bortezomib
20 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Completed NCT02249676 Phase 2
21 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
22 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
23 Hematopoietic Stem Cell Transplant in Devic's Disease Active, not recruiting NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
24 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
25 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
26 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
27 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
28 Central Pain Study for ABX-1431 Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
29 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
30 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
31 Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 Not yet recruiting NCT03605238 Phase 1
32 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Withdrawn NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
33 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
34 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377
35 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
36 Pathologic-MRI Findings in Atypical IIDD Completed NCT03121105
37 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
38 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
39 Pediatric NMOSD Observational Study Recruiting NCT03766347
40 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
41 The French Multiple Sclerosis Registry Recruiting NCT02889965
42 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
43 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541 Not Applicable
44 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
45 Scrambler Trial for Pain in NMOSD Active, not recruiting NCT03452176 Not Applicable
46 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
47 Optical Coherence Tomography and Optic Neuritis (OCTON) Active, not recruiting NCT02573792
48 Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China Enrolling by invitation NCT03514030
49 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867 Not Applicable
50 Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital Not yet recruiting NCT03819413

Search NIH Clinical Center for Neuromyelitis Optica

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neuromyelitis Optica cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neuromyelitis optica

Genetic Tests for Neuromyelitis Optica

Anatomical Context for Neuromyelitis Optica

MalaCards organs/tissues related to Neuromyelitis Optica:

42
Brain, Spinal Cord, Eye, T Cells, B Cells, Thyroid, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Neuromyelitis Optica:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Neuromyelitis Optica

Articles related to Neuromyelitis Optica:

(show top 50) (show all 2049)
# Title Authors Year
1
Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis. ( 30846436 )
2019
2
Callosal lesions on magnetic resonance imaging with multiple sclerosis, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis. ( 31030018 )
2019
3
Clinical Approach to Pediatric Transverse Myelitis, Neuromyelitis Optica Spectrum Disorder and Acute Flaccid Myelitis. ( 31109018 )
2019
4
Neuromyelitis optica spectrum disorder with lung adenocarcinoma and intraductal papillary mucinous neoplasm. ( 31060025 )
2019
5
Neuromyelitis optica spectrum disorder and adenocarcinoma of ovary: a novel association. ( 31023729 )
2019
6
Case report: an area postrema syndrome revealing a neuromyelitis optica spectrum disorder associated with central nervous system tuberculosis in a young Togolese (black African) woman. ( 30971218 )
2019
7
Neuromyelitis optica: an elusive cause of dysphagia. ( 30642856 )
2019
8
Hemorrhagic encephalitis in a patient with neuromyelitis optica: A case report. ( 30985265 )
2019
9
Limbic encephalitis-like presentation in neuromyelitis optica spectrum disorder: a case report. ( 30835052 )
2019
10
Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder. ( 30745445 )
2019
11
A case of neuromyelitis optica spectrum disorder following seasonal influenza vaccination. ( 30769255 )
2019
12
Coexistence of Neuromyelitis Optica and Amyotrophic Lateral Sclerosis: A Case Report. ( 30671163 )
2019
13
A Little-Known Brain Imaging Feature in Neuromyelitis Optica Spectrum Disorder: A Leukodystrophy-Like Pattern. ( 30877700 )
2019
14
Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanoma. ( 31030016 )
2019
15
Corrigendum to "Foxp3+ regulatory T cells expression in Neuromyelitis optica spectrum disorders" [Multiple Sclerosis and Related Disorders 30 (2019) 114-118]. ( 30987752 )
2019
16
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. ( 30962374 )
2019
17
The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. ( 30800132 )
2019
18
Can Visual Testing Be Used to Distinguish Neuromyelitis Optica and Multiple Sclerosis? ( 30803517 )
2019
19
Comparison of Ocular Motor Findings Between Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Involving the Brainstem and Cerebellum. ( 30827013 )
2019
20
Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea. ( 30746915 )
2019
21
Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. ( 30770971 )
2019
22
Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. ( 30698295 )
2019
23
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. ( 30663608 )
2019
24
Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis. ( 30408268 )
2019
25
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. ( 30377816 )
2019
26
Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. ( 30060979 )
2019
27
Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. ( 30825049 )
2019
28
Sequential Optic Neuritis: A Neuromyelitis Optica Spectrum Disorder. ( 30925966 )
2019
29
The association between dietary sugar intake and neuromyelitis optica spectrum disorder: A case-control study. ( 30978652 )
2019
30
Neuromyelitis optica spectrum disorder in a tertiary hospital in the Philippines: a case series. ( 30981191 )
2019
31
Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. ( 30981824 )
2019
32
Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients. ( 30995203 )
2019
33
Cerebral cortex impairment in neuromyelitis optica spectrum disorder: A case report and literature review. ( 31005027 )
2019
34
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( 31005713 )
2019
35
Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset. ( 31012355 )
2019
36
A case where selective plasma exchange for neuromyelitis optica was effective. ( 31025803 )
2019
37
Role of Glutamatergic Excitotoxicity in Neuromyelitis Optica Spectrum Disorders. ( 31031597 )
2019
38
Neuromyelitis optica spectrum disorder with area postrema syndrome. ( 31041136 )
2019
39
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. ( 31050279 )
2019
40
Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. ( 31056665 )
2019
41
Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls. ( 31063950 )
2019
42
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Neuromyelitis Optica Spectrum Disorder in a 6-Year-Old Boy. ( 31064015 )
2019
43
Neuromyelitis optica spectrum disorder in three generations of a Chinese family. ( 31075495 )
2019
44
Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder. ( 31079538 )
2019
45
HLA-alleles class I and II associated with genetic susceptibility to neuromyelitis optica in Brazilian patients. ( 31090804 )
2019
46
A comparison between spinal cord infarction and neuromyelitis optica spectrum disorders: Clinical and MRI studies. ( 31092838 )
2019
47
Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. ( 31103517 )
2019
48
Resolution of inflammation in neuromyelitis optica spectrum disorders. ( 30300851 )
2019
49
Altered neurovascular coupling in neuromyelitis optica. ( 30315685 )
2019
50
MRI findings in pediatric neuromyelitis optica spectrum disorder with MOG antibody: Four cases and review of the literature. ( 30447856 )
2019

Variations for Neuromyelitis Optica

Expression for Neuromyelitis Optica

Search GEO for disease gene expression data for Neuromyelitis Optica.

Pathways for Neuromyelitis Optica

GO Terms for Neuromyelitis Optica

Cellular components related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.46 AQP4 HLA-DRB1 IL17A MOG
2 cell surface GO:0009986 9.35 CD59 HLA-DPB1 HLA-DRB1 MBP SLC1A2
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.32 HLA-DPB1 HLA-DRB1
4 MHC class II protein complex GO:0042613 9.26 HLA-DPB1 HLA-DRB1
5 ER to Golgi transport vesicle membrane GO:0012507 8.8 CD59 HLA-DPB1 HLA-DRB1

Biological processes related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.76 HCRT IL17A IL6 TNFSF13B
2 T cell receptor signaling pathway GO:0050852 9.58 HLA-DPB1 HLA-DRB1 MOG
3 central nervous system development GO:0007417 9.5 MBP MOG S100B
4 positive regulation of interleukin-6 secretion GO:2000778 9.48 IL17A MBP
5 water transport GO:0006833 9.43 AQP1 AQP4
6 positive regulation of glial cell proliferation GO:0060252 9.37 GFAP IL6
7 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.26 HLA-DPB1 HLA-DRB1
8 multicellular organismal water homeostasis GO:0050891 9.16 AQP1 AQP4
9 positive regulation of T cell proliferation GO:0042102 9.13 HLA-DPB1 IL6 TNFSF13B
10 immune response GO:0006955 9.1 HLA-DPB1 HLA-DRB1 IL17A IL6 MBP TNFSF13B

Molecular functions related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 channel activity GO:0015267 9.16 AQP1 AQP4
2 water channel activity GO:0015250 8.96 AQP1 AQP4
3 water transmembrane transporter activity GO:0005372 8.62 AQP1 AQP4

Sources for Neuromyelitis Optica

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....